Abstract
Patients with rheumatoid arthritis (RA) are at high risk of cardiovascular events. Platelet biomarkers are involved in inflammation, atherosclerosis and thrombosis. Cardiovascular and RA-associated factors can alter the structure and function of platelets, starting from megakaryocytopoiesis. Reactive megakaryocytopoiesis increases circulating platelets count and triggers hyperactivity. Hyperactive platelets target synovial membranes with subsequent local rheumatoid inflammation. Hyperactive platelets interact with other cells, and target the vascular wall. Accumulating evidence suggests that disease modifying anti-rheumatic drugs (DMARD) decrease platelet activity. © Springer-Verlag 2010.
| Original language | English |
|---|---|
| Pages (from-to) | 153-164 |
| Number of pages | 11 |
| Journal | Rheumatology International |
| Volume | 31 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biomarkers
- Cardiovascular risk
- Inflammation
- Platelet function
- Rheumatoid arthritis
Fingerprint
Dive into the research topics of 'Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver